Skip to main content
Appili Therapeutics Inc. logo

Appili Therapeutics Inc. — Investor Relations & Filings

Ticker · APLI TSX Manufacturing
Filings indexed 247 across all filing types
Latest filing 2024-10-10 Regulatory Filings
Country CA Canada
Listing TSX APLI

About Appili Therapeutics Inc.

https://appilitherapeutics.com/

Appili Therapeutics Inc. is a biopharmaceutical company focused on the acquisition and development of novel medicines targeting unmet needs across a broad spectrum of infectious diseases and biodefense. The company advances anti-infective therapies to provide solutions for patients and healthcare providers. Its pipeline includes LIKMEZ™ (ATI-1501), a novel oral taste-masked suspension of metronidazole for serious anaerobic and protozoal infections; ATI-1701, a potential first-in-class live-attenuated vaccine for tularemia (a serious biothreat); and ATI-1801, a novel topical antiparasitic product designed to treat disfiguring skin infections.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2024-10-10 English
News release - English.pdf
Regulatory Filings
2024-10-10 English
Other material contracts (amended) - English.pdf
Regulatory Filings
2024-09-03 English
Notice of meeting - English.pdf
Regulatory Filings
2024-08-21 English
Other.pdf
Regulatory Filings
2024-08-21 English
Form of proxy - English.pdf
Regulatory Filings
2024-08-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.